Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A method of treating a subject having a cystic fibrosis transmembrane conductance regulator (CFTR) protein-mediated condition or symptom treatable by inhibiting CFTR-mediated ion transport, the method comprising administering to the subject a therapeutically effective amount of a compound of formula ~~(I)~~(Ic):



(I)



(Ic)

wherein ~~X_1, X_2 and X_3 are independently chosen from hydrogen, an organic group, a halo group, a nitro group, an azo group, a hydroxyl group and a mercapto group;~~ Y_1, Y_2 and Y_3 are independently chosen from hydrogen, ~~an organic group,~~ an aliphatic group, a halo group, a nitro group, an azo group, a hydroxyl group and a mercapto group; ~~A_1 and A_2 are independently chosen from oxygen and sulfur, A_3 is chosen from sulfur and selenium; and A_4 comprises one or more carbons or heteroatoms and may be present or absent;~~ or a pharmaceutically acceptable ~~derivative~~ salt thereof, as an individual stereoisomer or a mixture thereof.

2. (Original) The method of claim 1, wherein the condition or symptom is associated with aberrantly increased intestinal secretion.

3. (Original) The method of claim 2, wherein the condition or symptom is secretory diarrhea.

4. - 7. (Canceled)

8. (Currently Amended) The method of claim ~~7~~1, wherein ~~X_1 is selected from the group consisting of a perfluoroalkyl group and a fluoro group~~the trifluoromethyl group is located at the 2, 3, or 4 position of the phenyl group to which it is attached.

9. (Currently Amended) The method of claim 8, wherein Y_2 is ~~chosen from~~ alkyl, hydroxyl, carboxyl, nitro, carbonate, carbamate, alkoxy, alkylcarbonyl, ~~and~~ or a halo group.

10. (Currently Amended) The method of claim ~~7~~8, wherein ~~X_1 is a 3-trifluoromethyl group~~the trifluoromethyl group is located at the 3 position.

11. (Currently Amended) The method of ~~claim 6~~ claim 1, wherein Y_2 is a hydroxyl group.

12. (Original) The method of claim 11, wherein Y_1 is a hydroxyl group.

13. (Original) The method of claim 11, wherein Y_1 is a bromo group.

14. (Original) The method of claim 11, wherein Y_3 is a nitro group.

15. –18. (Canceled)

19. (Currently Amended) The method of claim 1, wherein the compound of formula ~~(I)~~(Ic) is ~~chosen from~~:


;


;


;


;


; or


.

20. – 43. (Canceled)

44. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a thiazolidinone compound—, wherein the thiazolidinone compound ~~independently chosen from:~~is 3-[(3-trifluoromethyl)phenyl]-5-[(4-nitrophenyl)methylene]-2-thioxo-4-thiazolidinone; 3-[(3-trifluoromethyl)phenyl]-5-[(4-oxycarboxyphenyl)methylene]-2-thioxo-4-thiazolidinone; 3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone; 3-[(3-trifluoromethyl)phenyl]-5-[(3,4-dihydroxyphenyl)methylene]-2-thioxo-4-thiazolidinone; 3-[(3-trifluoromethyl)phenyl]-5-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-thioxo-4-thiazolidinone; ~~and~~ or 3-[(3-trifluoromethyl)phenyl]-5-[(3-bromo-4-hydroxy-5-nitrophenyl)methylene]-2-thioxo-4-thiazolidinone~~; and at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant~~.

45. (Original) The composition of claim 44, wherein the composition does not contain detectable dimethyl sulfoxide.

46. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (~~H~~c):



(I)



(Ic)

wherein ~~X_1, X_2 and X_3 are independently chosen from hydrogen, an organic group, a halo group, a nitro group, an azo group, a hydroxyl group and a mercapto group;~~ Y_1, Y_2 and Y_3 are independently chosen from hydrogen, an aliphatic group, ~~an organic group,~~ a halo group, a nitro group, an azo group, a hydroxyl group and a mercapto group; ~~A_1 and A_2 are independently chosen from oxygen and sulfur, A_3 is chosen from sulfur and selenium; and A_4 comprises one or more carbons or heteroatoms and may be present or absent;~~ or a pharmaceutically acceptable ~~derivative~~ salt thereof, as an individual stereoisomer or a mixture thereof~~;~~.

~~provided, however, that when:~~

~~1) A_4 is absent, A_1 and A_2 are each oxygen, A_3 is sulfur, one of X_1, X_2, and X_3 is trifluoromethyl or chloro in the 4-position and the others of X_1, X_2, and X_3 are each hydrogen, one of Y_1, Y_2, and Y_3 can not be 4-methylpiperazin-1-yl in the 2-position when the remaining others of Y_1, Y_2, and Y_3 are each hydrogen;~~

~~2) A_4 is absent, A_1 and A_3 are each sulfur, A_2 is oxygen, one of X_1, X_2, and X_3 is carboxyl in the 4-position and the others of X_1, X_2, and X_3 are each hydrogen, Y_1, Y_2, and Y_3 can not each be hydrogen;~~

~~3) A_4 is absent, A_1 and A_3 are each sulfur, A_2 is oxygen, one of X_1, X_2, and X_3 is hydroxy in the 2-, 3- or 4-position or ethoxy in the 4-position and the others of X_1, X_2, and X_3 are each hydrogen, one of Y_1, Y_2 and Y_3 is hydrogen, and another of Y_1, Y_2 and Y_3 is hydroxy or methoxy in the 4-position, the remaining one of Y_1, Y_2 and Y_3 can not be methoxy in the 3-position; and~~

~~4) A_4 is absent, A_1 and A_3 are each sulfur, A_2 is oxygen, one of X_1, X_2, and X_3 is methyl in the 4-position and another of X_1, X_2, and X_3 is chloro in the 3-position, one of Y_1, Y_2 and Y_3 is methoxy in the 4-position, the remaining others of Y_1, Y_2 and Y_3 can not each be hydrogen;~~

~~and at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent,~~ and ~~a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.~~

47. – 49. (Canceled)

50. (Currently Amended) The composition of ~~claim 47~~claim 46, wherein Y_2 is ~~chosen from~~ an alkyl, hydroxyl, carboxyl, nitro, carbonate, carbamate, alkoxy, alkylcarbonyl, ~~and~~ or a halo group.

51. (Currently Amended) The composition of ~~claim 47~~claim 46, wherein the trifluoromethyl group is located at the 2, 3, or 4 position of the phenyl group to which it is attached~~X_1 is a 3-trifluoromethyl group~~.

52. (Currently Amended) The composition of ~~claim 47~~claim 50, wherein Y_2 is a hydroxyl group.

53. (Original) The composition of claim 52, wherein Y_1 is a hydroxyl group.

54. (Original) The composition of claim 52, wherein Y_1 is a bromo group.

55. (Original) The composition of claim 54, wherein Y_3 is a nitro group.

56. – 58. (Canceled)

59. (Currently Amended) The composition of ~~claim 57~~claim 51, wherein ~~X_1 is a 3-trifluoromethyl group~~the trifluoromethyl group is located at the 3 position.

60. (Original) The composition of claim 46, wherein the composition does not contain detectable dimethyl sulfoxide.

61. – 64. (Canceled)